About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Part 2: J. Russell May, PharmD
In the second of a three-part series, topics such as drug approvals and shortages, therapeutic interchanges, and pharmacoeconomic assessments are discussed.
C. Lee Ventola, MS
Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths
Research has addressed individual ADHD drugs, but few head-to-head trials have been conducted. In a meta-analysis of 32 trials, variable drug effects were noted.
Stephen V. Faraone, PhD
Valuable Insight or Government Intrusion?
Comparative effectiveness research has the potential to direct health care spending toward effective therapies and to assist P&T committees. However, some experts question its potential benefit, and others say that collecting the evidence might not be that easy.
F. Randy Vogenberg, RPh, PhD
Pay-for-Delay and Authorized Generics Back in the Spotlight
Blogs in health care and law are abuzz over a bill to restrict drug companies from “pay-for-delay” patent settlements that postpone the introduction of generics.
Parenteral nicardipine for hypertension, omalizumab for asthma, and acquired coagulopathy from the use of topical bovine thrombin are discussed.
Drugs discussed include ofatumumab, pazopanib, and a C1 esterase inhibitor.
Marvin M. Goldenberg, PhD, RPh, MS
David B. Nash, MD, MBA, discusses the failing grade that Consumers Union (CU), publisher of Consumer Reports, has given to our present health care system — and the CU’s recommendations for reform.
David B. Nash, MD, MBA
Getting to the ‘Route’ of the Problem
Matthew Grissinger, RPh, FASCP, explains how to avoid mixups with intravenous and epidural routes of administration for potassium chloride.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses some proposed changes to Medicare’s Part D program that could make formulary design more flexible and grant more authority to P&T committees.
From Colcrys to Voreloxin, P&T presents the latest studies and information about FDA approvals, drug indications, product recalls, and industry updates.